Clinical Trial Update: Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing meloxicam suppository and tablet to indomethacin suppository for efficacy and safety in ankylosing spondylitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Indomethacin suppository (indomethacin)
• MELOXICAM (MELOXICAM)
• Meloxicam Tablet (meloxicam)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: COMPLETED